Markets

NeOnc Technologies Signs MoU With Abu Dhabi's Health Department Over Development Research And Clinical Capability In Oncology, Centrla Nervous System Therapeutics

Oct 21, 2026 · 08:02 AM ET· updated 1h ago

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that

Why It Matters

NeOnc signed an agreement with Abu Dhabi to work together on brain cancer treatments. This shows the company is building partnerships and moving its research forward internationally.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NTHI2.71

-0.01 (-0.44%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.